Medical Services International Increases Profit by 208% With an 8 Cent EPS for Fiscal Year 2001.Business Editors EDMONTON, Alberta--(BUSINESS WIRE)--Dec. 19, 2001 Medical Services International Inc. (Pink Sheets:MSITF) is pleased to announce its financial results for the year ending June 30, 2001. Total revenue increased by 41% from $954,859 last year to $1,347,705 this year. Total revenue includes income from operations as well as the proceeds received from the sale of the Companies interest in International Biotech Corporation. Net Income for the year increased by 208% from $208,608 to $642,484. The earnings per share on a weighted average increased from $.03 per share to $.08 per share. The net asset base of the company increased by 11% from $11,599,640 to $12,926,174 which gives the Company a breakup value Breakup value See: Private market value. breakup value The market value of all the individual parts of a firm if the firm were to be broken up and the individual parts operated independently. in excess of $.80 per share. President Robert Talbot said, "The Company had an excellent year showing record profits. This is the fourth consecutive year that the Company has shown a profit. The growth of the Company is expected to continue over the next year as new and expanded divisions in the Company come on line." About Medical Services Medical Service International Inc. operates medical facilities on Anguilla, B.W.I. that supply medical diagnostic services diagnostic services, n.pl the imaging and laboratory capabilities available for determining the cause of an illness. and dialysis. The facility combines the recreational aspects of a Caribbean destination with the availability of North American North American named after North America. North American blastomycosis see North American blastomycosis. North American cattle tick see boophilusannulatus. quality medical services. In response to a worldwide demand for less costly, rapid technically simplified test methods for infectious diseases the company has developed its Vscan rapid test kits for the detection of HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. 1 & 2, Hepatitis B Hepatitis B Definition Hepatitis B is a potentially serious form of liver inflammation due to infection by the hepatitis B virus (HBV). It occurs in both rapidly developing (acute) and long-lasting (chronic) forms, and is one of the most common chronic and C and Tuberculous tuberculous /tu·ber·cu·lous/ (too-ber´ku-lus) pertaining to or affected with tuberculosis; caused by Mycobacterium tuberculosis. tu·ber·cu·lous adj. 1. . It is estimated that over 30 million individuals have HIV and do not know it. It is estimated that there are 200 million people current living with Hep C and have no idea they are infected. Of the individuals that are HIV positive statistics show that over 30% have Tuberculous (TB) which is highly contagious but can be treated. The Vscan test kits can be used anywhere and give results in under 10 minutes. Medical Services International Inc. trades in the United States on the NQB NQB National Quotation Bureau, Inc (now Pink Sheets) Pink Sheets under the symbol "MSITF". For further information, please contact Robert Talbot at 780/430-6363. Note: Certain statements in this news release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Such statements involve known and unknown risks, uncertainties and other factors that may cause results to differ materially. Such risks, uncertainties and other factors include, but are not limited to new economic conditions, risk in product technology developments, market acceptance of new product and continuing product demand, level of competition and other factors described in the company reports, prospectus and other filings with the Securities and Exchange Commission. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion